Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Horizon Therapeutics Public Limited Company - Ordinary Shares (NQ: HZNP )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Horizon Therapeutics Public Limited Company - Ordinary Shares

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Benzinga's Top Ratings Upgrades, Downgrades For August 4, 2022
Upgrades 
Via Benzinga
Nasdaq Surges Over 300 Points; Moderna Earnings Beat Expectations
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 300 points on Wednesday. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
  
Via Benzinga
Horizon Therapeutics' Shares Tumble On Q2 Miss, Trimmed FY22 Outlook
Via Benzinga
Analyst Ratings for Horizon Therapeutics
Analysts have provided the following ratings for Horizon Therapeutics (NASDAQ:HZNP) within the last quarter: 
Via Benzinga
Analyst Ratings for Horizon Therapeutics
Horizon Therapeutics (NASDAQ:HZNP) has observed the following analyst ratings within the last quarter: 
Via Benzinga
This Biotechnology Stock Jumped Over 360%; Here Are 106 Biggest Movers From Yesterday
Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) shares surged 360.5% to settle at $19.80 on Wednesday on above-average volume. 
Via Benzinga
Why Poseida Therapeutics Is Trading Higher By Around 100%, Here Are 75 Stocks Moving In Wednesday's Mid-Day Session
Gainers Helius Medical Technologies, Inc. (NASDAQ: HSDT) shares jumped 167% to $1.72 after dropping 13% on Tuesday. 
Via Benzinga
Dow Jumps 350 Points; Crude Oil Drops Over 2%
U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 350 points on Wednesday. 
Via Benzinga
AMD, SolarEdge Technologies And Some Other Big Stocks Moving Lower On Wednesday
  Rocky Brands, Inc. (NASDAQ: RCKY) dipped 21.6% to $26.62 after the company reported worse-than-expected Q2 EPS results. 
Via Benzinga
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
  
Via Benzinga
Horizon Therapeutics: Q2 Earnings Insights
  Horizon Therapeutics (NASDAQ:HZNP) reported its Q2 earnings results on Wednesday, August 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Horizon Therapeutics plc Reports Second-Quarter 2022 Financial Results and Revises Full-Year 2022 Net Sales and Adjusted EBITDA Guidance
From Horizon Therapeutics plc
Via Business Wire
Biotech Investors: August's Key PDUFA Catalysts You Must Know
Regulatory decisions have yet to pick up pace this year. July’s calendar was light, but the good news was that most decisions turned out to be positive. That said, none of the drugs approved during the... 
Via Benzinga
Horizon Therapeutics plc Named a Best Company for Multicultural Women
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces Inaugural #RAREis Global Advocate Grant Recipients
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces Wanda Durant Has Joined Olympian Gail Devers to Raise Awareness of Thyroid Eye Disease Among Graves’ Disease Community
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics Receives FDA Approval For Uncontrolled Gout Candidate
The U.S. Food and Drug Administration (FDA) has approved Horizon Therapeutics’ (NASDAQ: HZNP) supplemental Biologics License Application (sBLA) for expanding the labeling to include KRYSTEXXA... 
Via Benzinga
FDA Approves KRYSTEXXA® (pegloticase) Injection Co-Administered With Methotrexate, Expanding the Labeling to Help More People with Uncontrolled Gout Achieve a Complete Response to Therapy
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc to Release Second-Quarter 2022 Financial Results and Host Webcast on Aug. 3, 2022
From Horizon Therapeutics plc
Via Business Wire
Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates
The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment. 
Via Benzinga
New Analysis Finds UPLIZNA® (inebilizumab) Effective Among European Populations with Neuromyelitis Optica Spectrum Disorder (NMOSD)
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Submits Regulatory Filing for UPLIZNA® (inebilizumab) in Brazil
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Named One of the Fortune Best Workplaces in Chicago™
From Horizon Therapeutics plc
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2022
Upgrades 
Via Benzinga
Analysis of Pooled Data from TEPEZZA® (teprotumumab-trbw) Clinical Trials Reinforces Safety Profile in People with Thyroid Eye Disease (TED)
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Named a Top Company for Executive Women
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc to Present at the Goldman Sachs 43rd Annual Global Health Care Conference
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc to Highlight Data and Education on Thyroid Eye Disease (TED) at the Endocrine Society (ENDO) 2022 Annual Conference
From Horizon Therapeutics plc
Via Business Wire
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.